Please assess the completion status of the following clinical trial:

Trial Title: IBI188 Combination Therapy in Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with locally advanced or metastatic solid tumors cannot be cured by surgery or other local treatments .~2. Aged ≥ 18 years (≥ 12 years is acceptable in Cohort C).~3. Able to provide archived or fresh tumor tissue samples for biomarker assessment.~4. Have at least one measurable lesion according to RECIST version 1.1.~5. ECCG PS score of 0-2.~6. Adequate organ and bone marrow functions .~7. Life expectancy ≥ 12 weeks.~8. Female subjects of childbearing potential or male subjects with partners of childbearing potential should take effective contraceptive measures throughout the whole treatment period and until 6 months after treatment.~9. Must voluntarily sign the Informed Consent Form (ICF), and be able to follow all study requirements and procedures. For the subjects enrolled in Cohort C who are ≥ 12 and \< 18 years old, in addition to obtaining the child's own consent, their guardians should provide informed consent and sign the ICF.~Exclusion Criteria:~1. Previous exposure to any CD47 antibody, SIRPα antibody, CD47/SIRPα recombinant protein or other inhibitors that act in the same pathway.~2. Previous exposure to any anti-programmed death receptor 1 (PD-1) or anti-programmed death-ligand (PD-L1) antibody (except Cohort C).~3. Concurrent participation in another clinical study.~4. The last dose of anti-tumor therapy is within 4 weeks before the first dose of study treatment.~5. Have undergone major surgical procedures within 4 weeks prior to the first dose of study treatment or planned to receive major surgery during the study treatment.~6. Presence of toxicities (excluding alopecia and fatigue) induced by previous anti-tumor therapy that has not recovered to Grade 0 or 1 as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 prior to the first dose of study treatment.~7. Known hypersensitivity to IBI188 or any ingredient in the study drug product.~8. History of other primary malignancies.~9. Female subjects who are pregnant or lactating.~10. Other ineligible conditions considered by the investigator.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): None
- Cohort B (Type: EXPERIMENTAL): None
- Cohort C (Type: EXPERIMENTAL): None
- Cohort D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).